UK Authorizes ‘Gamechanger’ AstraZeneca Vaccine Despite Data Doubts
MHRA Rejects Low Dose Data
Executive Summary
UK regulator admits evidence sparse on older patients, but believes longer gap between doses can boost efficacy and accelerate numbers of people immunized.
You may also be interested in...
The Top Five (Non-COVID) Pharma Stories Of 2020
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest major developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Speedy Clearance Of COVID-19 Vaccines Concerns Experts In India
No one wants to take away from India’s flair and prowess in the vaccines segment, but there should be no place for doubt when it comes to rigor in scientific and regulatory processes. Experts have raised questions around the restricted emergency use clearance of two COVID-19 vaccines in India.